Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 7/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | PNP | P00491 | 2/20 | 0.42 |
| ▸ | NT5E | P21589 | 2/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22337175 | 0.92 | HINT1 (0.49) | HINT1TAS1R3TAS1R1HPGDGSK3A | |
| SCHEMBL26808279 | 0.86 | HINT1 (0.49) | HINT1TAS1R3TAS1R1HPGDGSK3A | |
| SCHEMBL26808568 | 0.85 | HINT1 (0.51) | HINT1TAS1R3TAS1R1HPGDGSK3A | |
| SCHEMBL26808591 | 0.85 | KDM4E (0.44) | HINT1TAS1R3TAS1R1TAAR1NT5E | |
| SCHEMBL26624267 | 0.84 | HINT1 (0.49) | HINT1TAS1R3TAS1R1HPGDGSK3A | |
| SCHEMBL26808575 | 0.84 | SLC29A1 (0.38) | HINT1 | |
| SCHEMBL26808538 | 0.83 | ADORA1 (0.49) | NT5E | |
| SCHEMBL25807955 | 0.83 | HINT1 (0.51) | HINT1TAS1R3TAS1R1HPGDGSK3A | |
| SCHEMBL16471919 | 0.83 | HINT1 (0.51) | HINT1TAS1R3TAS1R1HPGDGSK3A | |
| SCHEMBL26808492 | 0.83 | HINT1 (0.51) | HINT1TAS1R3TAS1R1HPGDGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357306-A1 | SYNTHESIS OF 1,2,5-TRI-O-BENZOYL-3-DIBENZYLAMINO-3-DEOXYRIBOSE AS INTERMEDIATE FOR PRODUCING 3'-AMINO-3'-DEOXYADENOSINE AND 3'-AMINO-3'-DEOXYGUANOSINE AND THE PROTECTED DERIVATIVES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357306-A1 | SYNTHESIS OF 1,2,5-TRI-O-BENZOYL-3-DIBENZYLAMINO-3-DEOXYRIBOSE AS INTERMEDIATE FOR PRODUCING 3'-AMINO-3'-DEOXYADENOSINE AND 3'-AMINO-3'-DEOXYGUANOSINE AND THE PROTECTED DERIVATIVES THEREOF | STING1, CGAS, AMPD3 | HINT1 152/4885TAS1R3 484/4885TAS1R1 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.